🔎 Trials Near Me

Beranda › Kanker Kandung Kemih › Oklahoma › Oklahoma City

Uji klinis Kanker Kandung Kemih di Oklahoma City, OK

11 studi untuk Kanker Kandung Kemih mencari peserta di lokasi sekitar Oklahoma City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

The Vanguard Study: Testing a New Way to Screen for Cancer

Menerima pesertaSukarelawan sehat diterima
  • University of Oklahoma Health Sciences Center, Oklahoma City
Usia 45 hingga 75 · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06995898

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Menerima pesertaFase 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06770582

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Menerima pesertaFase 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07000084

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Mercy Hospital Oklahoma City, Oklahoma City
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Menerima pesertaFase 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07061964

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Menerima pesertaFase 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT03866382

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Menerima pesertaFase 1
  • University of Oklahoma - Health Sciences Center, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT05614739

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Menerima pesertaFase 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07097142

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Menerima pesertaFase 2
  • OU Health Stephenson Cancer Center, Oklahoma City
  • OU Medical Center, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT04879329

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Menerima pesertaFase 1
  • OU Health University of Oklahoma Medical Center, Oklahoma City
  • Stephenson Cancer Center (chemo location), Oklahoma City
  • University of Oklahoma Health Science Center, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Menerima pesertaStudi observasional
  • Mercy Hospital - OKC, Oklahoma City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT07327489

Uji klinis Kanker Kandung Kemih di kota lain

Studi lain di Oklahoma City

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.